
Vitreoretinal surgery has been the most astoundingly innovative subspecialty of ophthalmology in recent times and European ophthalmologists have been and are continuing to play major roles in keeping this an exciting and dynamic field.
Vitreoretinal surgery has been the most astoundingly innovative subspecialty of ophthalmology in recent times and European ophthalmologists have been and are continuing to play major roles in keeping this an exciting and dynamic field.
Our aims are to :
The 21st European VitreoRetinal Society (EVRS) Meeting, scheduled to take place in Budapest, Hungary, from the 14th to the 17th of November 2024.
Following a period of virtual only engagements due to COVID-19, the 20th EVRS Meeting successfully returned to a live and hybrid format in Cappadocia in September 2023. The event witnessed enthusiastic participation from over 500 delegates representing 80 different countries, reaffirming EVRS’s global appeal. The live surgery, courses, symposia and scientific sessions covering the latest advancements in surgical and medical retina, combined surgery, and imaging were well-received by the ophthalmic community and participating companies.
Our meticulously chosen congress venue in Budapest offers state-of-the-art facilities, complemented by the convenience of a flagship Novotel Hotel. Budapest, with its rich history, iconic bridges and captivating castle, provides an ideal backdrop for this prestigious event. We are confident that the allure of Budapest will attract a substantial number of ophthalmologists from around the world.
Themed “Evidence-based vs. my way in Retina,” the meeting aims to explore the latest developments in surgical and medical retina, combined cataract and retina surgery, as well as retinal imaging.
Trending Topic
On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.